Hina 39s Leading Provider Of Cord Blood Collection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HONG KONG, June 17, 2022 /PRNewswire/ Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib. Details related to this news can be found via the following Cellenkos news announcement: Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis (prnewswire.com) Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC commented, "T ....

William Zima , Cellenkos Inc , Investor Relations Department , Drug Administration , Icr Inc , Global Cord Blood Corporation , Prnewswire Global Cord Blood Corporation , Cord Blood Corporation , Investigational New Drug , Ting Zheng , Chief Executive Officer , Global Cord Blood , Cord Blood , Hong Kong , June 17 , 022 Prnewswire Global Cord Blood Corporation Nyse Co Quot Gcbc Or The Company , Hina 39s Leading Provider Of Cord Blood Collection , Laboratory Testing , Ematopoietic Stem Cell Processing And Storage Services , S Pleased To Announce That Cellenkos , Nc Quot Clnk Recently Announced That The Us Food And Drug Administration Fda Has Cleared Its Investigational New Ind Application To Initiatea Phase1b , Pen Label Study Of Ck0804 As An Add On Therapy To Ruxolitinib In Patients With Myelofibrosis Who Experiencea Suboptimal Response Details Related This News Can Be Found Via The Following Cellenkos Announcement Receives Fda Clearance Investigational New Drug Ind Application For Treatment Prnewswire Com Ms Ting Zheng , Hief Executive Officer And Chairperson Of Gcbc Commented , Uot The Global Cord Blood Team Is Encouraged By Above News Announced Clnk Which Highlights Apotentially Transformative Treatment For Myelofibrosis Patients We Congratulate On This Development Quot About Corporation An Umbilical Banking Operator Serving Multiple Regions In China Provides Collection , Ematopoietic Stem Cell Processing And Storage Services For More Information , Lease Visit The Company 39s Website At Http Www Globalcordbloodcorp Com For More Information ,